Abstract
Methotrexate was the first truly effective systemic treatment for severe psoriasis when it was introduced into clinical practice in the 1960s [1], Since that time it has been widely employed to treat disabling psoriasis and it has held its own despite the development of alternative therapies over the years. The treatment of psoriasis with methotrexate has been comprehensively reviewed recently and clinical guidelines proposed [2, 3]. The drug is especially useful in acute generalised pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis inadequately controlled by topical therapy alone. It can be used as a short-term option to gain control of unstable forms of psoriasis such as pustular psoriasis or erythroderma before returning to other modes of treatment or, more commonly, as long-term, low dose, once weekly maintenance treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weinstein GD. Commentary: Three decades of folic acid antagonists in dermatology. Arch Dermatol 119:525–7.(1983).
Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 21:399–408.(1996).
Boffa MJ, Chalmers RJG. In: Gawkrodger DJ, ed. Current management of psoriasis. J Dermatol Treat 8:27–55(1997).
Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: Anti-inflammatory or antiproliferative? J Am Acad Dermatol 22:523–4 (1990).
Jeffes EWB, McCullough JL, Pittelkow MR et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 104:183–8 (1995).
Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Chem Clin Biochem 31:667–74 (1993).
Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 19:145–56(1988).
Boffa MJ, Chalmers RJG, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during longterm methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 133:774–8 (1995).
Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 135:538–44 (1996).
Boffa MJ, Chalmers RJG, Smith A. Type III procollagen aminopeptide should replace routine liver biopsy in monitoring long-term methotrexate therapy for psoriasis. Br J Dermatol 135:850 (1996).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Boffa, M.J. (1999). Methotrexate. In: Mallia, C., Uitto, J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4857-7_52
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4857-7_52
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7203-5
Online ISBN: 978-1-4615-4857-7
eBook Packages: Springer Book Archive